Last updated on March 2020

Study to Evaluate the Efficacy and Safety of Belviq XR in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents Age 12 to 17 Years


Brief description of study

This study will be conducted to demonstrate weight loss efficacy by change in body mass index (BMI) and safety in adolescents age 12 to 17 years (inclusive) during 52 weeks of treatment with Belviq XR 20 milligrams (mg) administered once daily (QD) as compared to placebo.

Clinical Study Identifier: NCT03338296

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.